Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia

Inclusion Criteria

• •1. Patients with relapsed and refractory acute B-lymphoblastic leukemia who have any of the following:
• •1. B-ALL patients with relapse (including bone marrow morphological relapse 1 and minimal residual relapse 2) after remission by chemotherapy or autologous stem cell transplantation;
• •2. Primary B-ALL patients who can not be completely relieved by more than two times of repeated chemotherapy;
• •3. High risk primary B-ALL patients who have not been relieved but are not suitable for re intensive therapy after 1-2 times of chemotherapy;
• •2. Flow cytometry (FCM) showed CD 22 positive in bone marrow or peripheral blood;
• •3. There should be at least one assessable lesion in B-ALL patients with simple extramedullary recurrence;
• •4. The activity state score of the Eastern Cooperative Oncology Group (ECOG) was less than or equal to 2;
• •5. The estimated survival time is more than 3 months;
• •6. Need to sign informed consent.